Page last updated: 2024-11-04

tramazoline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5524
CHEMBL ID32573
CHEBI ID134893
SCHEMBL ID121944
SCHEMBL ID8623881
MeSH IDM0046867

Synonyms (49)

Synonym
1h-imidazol-2-amine, 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-
tramazoline
PDSP2_001082
PDSP1_001098
CHEBI:134893
muconasal
CHEMBL32573 ,
L000866
D08624
tramazoline (inn)
muconasal (tn)
1082-57-1
n-(5,6,7,8-tetrahydronaphthalen-1-yl)-4,5-dihydro-1h-imidazol-2-amine
imidazolidin-2-ylidene-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine
(4,5-dihydro-1h-imidazol-2-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine
bdbm50027056
einecs 214-105-6
tramazolina
unii-sle31693iv
tramazoline [inn:ban]
tramazolinum [inn-latin]
rhynaspray
rhinol
tobispray
tramazolina [inn-spanish]
sle31693iv ,
tramazolinum
4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine
2-((5,6,7,8-tetrahydro-1-naphthyl)amino)-2-imidazoline
tramazoline [inn]
tramazoline [mi]
tramazoline [who-dd]
STL483756
SCHEMBL121944
SCHEMBL8623881
DTXSID5046936
2-(5,6,7,8-tetrahydro-1-naphthylimino)-imidazolidine
2-(5,6,7, 8-tetrahydro-1-naphthylimino)-imidazolidine
n-(5,6,7,8-tetrahydro-1-naphthalenyl)-4,5-dihydro-1h-imidazol-2-amine #
imidazolidine,2-[(5,6,7,8-tetrahydronaphthal-1-yl]imino-
2-[(5,6,7,8-tetrahydro-1-naphthyl)amino]-2-imidazoline
tramazolin
rhinol; rhynaspray; tobispray
DB13064
BCP29020
2-imidazolin-2-yl(5,6,7,8-tetrahydro-1-naphthyl)amine tramazoline 2-(5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline 4,5-dihydro-
Q412102
bdbm50225288
EN300-25745458

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI."( Comparison of hemostatic effect and safety between epinephrine and tramazoline during nasotracheal intubation: a double-blind randomized trial.
Hashimoto, M; Hoshijima, H; Kako, E; Kamimura, Y; Okuda, M; Okumura, Y; Sato-Boku, A; Sento, Y; Sobue, K; Suzuki, F; Tachi, N, 2021
)
0.86

Dosage Studied

ExcerptRelevanceReference
" The first ionization energies of the pharmacologically active 20-(phenylimino)imidazolidines do not correlate with hypotensive activity based on dosage data after intravenous administration to rats."( Ultraviolet photoelectron spectroscopy of cyclic amidines. 2. Electronic structure of clonidine and some related 2-(phenylimino)imidazolidines with alpha-adrenergic activity.
de Jong, AP; van Dam, H, 1980
)
0.26
" Hypotensive potency after intravenous administration to anesthetized, normotensive rats was determined as a measure of central alpha-adrenergic activity and expressed as pC25, obtained from log dose-response curves."( Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.
de Jonge, A; Lam, E; Slothorst-Grisdijk, FP; Timmermans, PB; van Meel, JC; van Zwieten, PA, 1981
)
0.26
" Attention should be paid to galenic properties and dosage of the active."( [The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters].
Klöcker, N; Rudolph, P; Sikora, C; Verse, T, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
tetralinsCompounds containing a tetralin skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.00420.00000.929610.0000AID35187
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.00420.00000.970810.0000AID35187
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.00420.00000.937510.0000AID35187
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID36786Binding affinity against Alpha-2 adrenergic receptor is the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was reported; 1.6*10e-81984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID197169Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID35187Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes1982Journal of medicinal chemistry, Dec, Volume: 25, Issue:12
alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs.
AID33252Peripheral hypertensive activity in pithed normotensive rats.1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.
AID183611First ionization energy by intravenous administration to rats1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Ultraviolet photoelectron spectroscopy of cyclic amidines. 2. Electronic structure of clonidine and some related 2-(phenylimino)imidazolidines with alpha-adrenergic activity.
AID3671650% inhibition of specific [3H]prazosin binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID186204Hypotensive activity by intravenous administration to rats1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Ultraviolet photoelectron spectroscopy of cyclic amidines. 2. Electronic structure of clonidine and some related 2-(phenylimino)imidazolidines with alpha-adrenergic activity.
AID33250Central hypotensive activity in anesthetized normotensive rats.1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.
AID23715Apparent partion coefficient of compound was evaluated in octanol/buffer at pH of 7.4 at 37 degree Centigrade1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
AID23716Partition coefficient (logD7.4)1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Characterization of alpha-adrenoceptor populations. Quantitative relationships between cardiovascular effects initiated at central and peripheral alpha-adrenoceptors.
AID197167Hypotensive activity (25% decrease in arterial pressure) after i.v. administration to anesthetized normotensive rats.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (64.52)18.7374
1990's5 (16.13)18.2507
2000's3 (9.68)29.6817
2010's2 (6.45)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.06 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index83.72 (26.88)
Search Engine Supply Index2.20 (0.95)

This Compound (50.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (21.21%)5.53%
Reviews2 (6.06%)6.00%
Case Studies2 (6.06%)4.05%
Observational0 (0.00%)0.25%
Other22 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Placebo-controlled Cross-over Trial of the Effect of Nasal Tramazoline With Dexamethasone in Obstructive Sleep Apnoea Patients [NCT01601509]23 participants (Actual)Interventional2010-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]